560 related articles for article (PubMed ID: 26364129)
21. Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases.
Rusch A; Ziltener G; Nackaerts K; Weder W; Stahel RA; Felley-Bosco E
Lung Cancer; 2015 Jan; 87(1):77-9. PubMed ID: 25468148
[TBL] [Abstract][Full Text] [Related]
22. BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
McGregor SM; McElherne J; Minor A; Keller-Ramey J; Dunning R; Husain AN; Vigneswaran W; Fitzpatrick C; Krausz T
Hum Pathol; 2017 Feb; 60():86-94. PubMed ID: 27771374
[TBL] [Abstract][Full Text] [Related]
23. Puzzling Results from
Rizzardi C; Athanasakis E; Cammisuli F; Monego SD; DE Spelorzi YCC; Costantinides F; Giudici F; Pinamonti M; Canzonieri V; Melato M; Pascolo L
Anticancer Res; 2017 Jun; 37(6):3073-3083. PubMed ID: 28551647
[TBL] [Abstract][Full Text] [Related]
24. Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma.
Cheung M; Talarchek J; Schindeler K; Saraiva E; Penney LS; Ludman M; Testa JR
Cancer Genet; 2013 May; 206(5):206-10. PubMed ID: 23849051
[TBL] [Abstract][Full Text] [Related]
25. Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma.
Andujar P; Pairon JC; Renier A; Descatha A; Hysi I; Abd-Alsamad I; Billon-Galland MA; Blons H; Clin B; Danel C; Debrosse D; Galateau-Sallé F; Housset B; Laurent-Puig P; Le Pimpec-Barthes F; Letourneux M; Monnet I; Régnard JF; Validire P; Zucman-Rossi J; Jaurand MC; Jean D
Mutagenesis; 2013 May; 28(3):323-31. PubMed ID: 23435014
[TBL] [Abstract][Full Text] [Related]
26. Genomic profiling of multiple primary cancers including synchronous lung adenocarcinoma and bilateral malignant mesotheliomas: Identification of a novel BAP1 germline variant.
Shinozaki-Ushiku A; Kohsaka S; Kage H; Oda K; Miyagawa K; Nakajima J; Aburatani H; Mano H; Ushiku T
Pathol Int; 2020 Oct; 70(10):775-780. PubMed ID: 32583627
[TBL] [Abstract][Full Text] [Related]
27. Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations.
Sneddon S; Dick I; Lee YCG; Musk AWB; Patch AM; Pearson JV; Waddell N; Allcock RJN; Holt RA; Robinson BWS; Creaney J
Lung Cancer; 2018 May; 119():64-70. PubMed ID: 29656754
[TBL] [Abstract][Full Text] [Related]
28. Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma.
Kalra N; Zhang J; Thomas A; Xi L; Cheung M; Talarchek J; Burkett S; Tsokos MG; Chen Y; Raffeld M; Miettinen M; Pastan I; Testa JR; Hassan R
BMC Cancer; 2015 May; 15():376. PubMed ID: 25952750
[TBL] [Abstract][Full Text] [Related]
29. The Rocky Road from Preclinical Findings to Successful Targeted Therapy in Pleural Mesothelioma.
Paajanen J; Bueno R; De Rienzo A
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362209
[TBL] [Abstract][Full Text] [Related]
30. Well-differentiated papillary mesothelioma: clustering in a Portuguese family with a germline BAP1 mutation.
Ribeiro C; Campelos S; Moura CS; Machado JC; Justino A; Parente B
Ann Oncol; 2013 Aug; 24(8):2147-50. PubMed ID: 23585512
[TBL] [Abstract][Full Text] [Related]
31. BAP1 gene mutations in Egyptian patients with advanced sporadic malignant pleural mesothelioma (MPM): relation with clinical outcomes and survival.
Bahnasy AA; El-Din RS; Sabri NA; Abdel-Rahman CA; Bastawisy AE
Cancer Genet; 2018 Dec; 228-229():83-92. PubMed ID: 30553477
[TBL] [Abstract][Full Text] [Related]
32. Contribution of BAP1 loss and p16 (CDKN2A) deletion analysis to the definitive diagnosis of mesothelioma in effusion cytology.
Aydogdu G; Özekinci S
Eur Rev Med Pharmacol Sci; 2023 Oct; 27(20):10001-10007. PubMed ID: 37916370
[TBL] [Abstract][Full Text] [Related]
33. Meningiomas in Patients With Malignant Pleural Mesothelioma Harboring Germline BAP1 Mutations.
Hu ZI; Miettinen M; Quezado M; Lebensohn AP; Aldape K; Agra M; Wagner C; Mallory Y; Hassan R; Ghafoor A
J Thorac Oncol; 2022 Mar; 17(3):461-466. PubMed ID: 34628055
[TBL] [Abstract][Full Text] [Related]
34. [Malignant mesothelioma and constitutional BAP1 gene mutations].
Neviere Z; Berthet P; Polycarpe F; Dubos-Arvis C; Dô P; Gervais R
Rev Mal Respir; 2019 Feb; 36(2):241-248. PubMed ID: 30686559
[TBL] [Abstract][Full Text] [Related]
35. Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition.
Srinivasan G; Sidhu GS; Williamson EA; Jaiswal AS; Najmunnisa N; Wilcoxen K; Jones D; George TJ; Hromas R
Cancer Chemother Pharmacol; 2017 Oct; 80(4):861-867. PubMed ID: 28756516
[TBL] [Abstract][Full Text] [Related]
36. Detecting germline BAP1 mutations in patients with peritoneal mesothelioma: benefits to patient and family members.
Kittaneh M; Berkelhammer C
J Transl Med; 2018 Jul; 16(1):194. PubMed ID: 30001711
[TBL] [Abstract][Full Text] [Related]
37. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival.
Baumann F; Flores E; Napolitano A; Kanodia S; Taioli E; Pass H; Yang H; Carbone M
Carcinogenesis; 2015 Jan; 36(1):76-81. PubMed ID: 25380601
[TBL] [Abstract][Full Text] [Related]
38. Genomic Deletion of
Sarun KH; Lee K; Williams M; Wright CM; Clarke CJ; Cheng NC; Takahashi K; Cheng YY
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30301262
[TBL] [Abstract][Full Text] [Related]
39. Recurrent Tumor Suppressor Alterations in Primary Pericardial Mesothelioma.
Schaefer IM; Mariño-Enríquez A; Hammer MM; Padera RF; Sholl LM
Mod Pathol; 2023 Sep; 36(9):100237. PubMed ID: 37295554
[TBL] [Abstract][Full Text] [Related]
40. Molecular characterization of localized pleural mesothelioma.
Hung YP; Dong F; Dubuc AM; Dal Cin P; Bueno R; Chirieac LR
Mod Pathol; 2020 Feb; 33(2):271-280. PubMed ID: 31371807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
